AQST
Aquestive Therapeutics, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.94-4.25%
Price as of Jul 20, 2026
AQST profitability
Aquestive Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 63.5%
- EBITDA margin
- -102.7%
- EBIT margin
- -111.2%
- Net margin
- -137.1%
- Free cash flow margin
- -88.2%
Returns
- Return on equity
- 202.4%
- Return on assets
- -48.8%
- Return on invested capital
- -56.2%
- Asset turnover
- 0.33x
Cash efficiency
- Cash from operations
- -$43.8M
- Cash per share
- $0.88
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.